A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

NCT04855201 | Terminated Phase 1 DMC FDA Drug

• 1 other identifier: 0367-CL-1101
• Study Type: interventional
• Target: 31
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to to evaluate the effect of ASP0367 on improvement of aerobic capacity relative to placebo, as well as evaluate the safety and tolerability of ASP0367 relative to placebo. This study will also evaluate the effect of ASP0367 on improvement of other aerobic capacity parameters relative to placebo, as well as evaluate the effect of ASP0367 on improvement of functional capacity relative to placebo.

Conditions

Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

Keywords

Maximum oxygen intake; Peak exercise; Bocidelpar

Outcome Measures

Primary Outcomes (6)

• Change from baseline in maximum oxygen uptake at peak exercise (VO2max) during Advanced Cardiopulmonary Exercise Test (aCPET)

  V02max is defined as maximum amount of oxygen body can utilize during exercise.

  Baseline and Week 6

• Safety and tolerability assessed by nature, frequency, and severity of Adverse Events (AEs)

  Adverse Events (AEs) will be coded using medical dictionary for regulatory activities (MedDRA). An AE is any untoward medical occurrence in a participant, temporally associated with the use of investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP. This includes events related to the comparator and events related to the (study) procedures.

  Baseline up to week 7

• Number of Participants With Laboratory Value Abnormalities and/or Adverse Events (AEs)

  Number of participants with potentially clinically significant laboratory values.

  Baseline up to week 7

• Number of Participants With Vital Sign Abnormalities and/or Adverse Events (AEs)

  Number of participants with potentially clinically significant vital signs values.

  Baseline up to week 7

• Number of Participants With 12-lead Electrocardiogram (ECG) Abnormalities and/or Adverse Events (AEs)

  Number of participants with potentially clinically significant 12-ECG values.

  Baseline up to week 7

• Number of participants with suicidal ideation and/or behavior as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

  The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician administered assessment tool that evaluates suicidal ideation and behavior. Number of participants that have an affirmative response provided to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods (not plan) without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 6 items for suicidal behavior (1. Actual attempt, 2. Interrupted attempt, 3. Aborted attempt, 4. Preparatory acts or behavior, 5. Suicidal Behavior 6. Completed suicide,) will be reported.

  Baseline up to week 7

Secondary Outcomes (5)

• Change from baseline in systemic oxygen extraction (SOE)

  Baseline and Week 6

• Change from baseline in percent predicted VO2max during aCPET

  Baseline and Week 6

• Change from baseline in workload at peak during aCPET

  Baseline and Week 6

• Change from baseline in workload at ventilatory anaerobic threshold (VAT) during aCPET

  Baseline and Week 6

• Change from baseline in multivariable gas exchange index (MGI) during SHAPE Test.

  Baseline and Week 6

Study Arms (2)

Bocidelpar (ASP0367)

EXPERIMENTAL

Participants will receive Bocidelpar (ASP0367) once daily in the morning for 6 weeks.

Drug: Bocidelpar

Placebo

PLACEBO COMPARATOR

Participants will receive placebo once daily in the morning for 6 weeks.

Drug: Placebo

Interventions

Bocidelpar DRUG

Oral

Also known as: MA-0211, ASP0367

Bocidelpar (ASP0367)

Placebo DRUG

Oral

Placebo

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Participant agrees and is able to adhere to the study requirements for the length of the study, including undergoing both aCPET and SHAPE Test.
• Participant has a body mass index (BMI) range of 17.0 to 36 kg/m\^2, inclusive and weighs at least 50 kg (male participant) or 40 kg (female participant) at screening.
• Participants with reduced maximum oxygen uptake due to poor SOE, defined as peak exercise (\[Ca-VO2\])/\[Hb\]) ≤ 0.85 and VO2max \< 85% predicted in the absence of a cardiac or pulmonary mechanical limit, determined by aCPET within 6 months prior to day 1 or participants with reduced maximum oxygen uptake due to poor SOE, defined as peak exercise (\[Ca-VO2\])/\[Hb\]) ≤ 0.85 and VO2max \< 85% predicted in the absence of a cardiac or pulmonary mechanical limit, determined by historical aCPET within 45 months of screening and confirmed reduction in skeletal muscle citrate synthase activity.
• Female participant is not pregnant and at least 1 of the following conditions apply:
• Not a woman of childbearing potential (WOCBP)
• WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 28 days after final IP administration.
• Female participant must agree not to breastfeed starting at screening and throughout the study period and for 28 days after final IP administration.
• Female participant must not donate ova starting at first dose of IP and throughout the study period and for 28 days after final IP administration.
• Male participant with female partner(s) of childbearing potential (including breastfeeding partner\[s\]) must agree to use contraception throughout the treatment period and for 28 days after final IP administration.
• Male participant must not donate sperm during the treatment period and for 28 days after final IP administration.
• Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 28 days after final IP administration.
• Participant agrees not to participate in another interventional study while participating in the present study.

You may not qualify if:

• Participant has signs and/or symptoms due to a cerebellar, pyramidal, extrapyramidal or other nonmyopathic process (e.g., cerebellar dysfunctions, movement disorder) that would interfere in any nontrivial manner with aCPET or SHAPE Test.
• Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
• Participant has any condition which makes the participant unsuitable for study participation.
• Participant has used moderate or strong inducers of CYP3A, CYP2C8 and CYP2C19 within the 3 months prior to day -1.
• Participant has cardiac troponin I (cTnI) \> ULN (or cardiac troponin T \> ULN if cTnI is not available) at screening.
• Participant has estimated glomerular filtration rate (eGFR) calculated by the modification of diet in renal disease equation \< 60 mL/min per 1.73 m\^2 at screening.
• Participant has at screening: total bilirubin (TBL) \> upper limit of normal (ULN) or transaminase(s) (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\]) \> ULN in the absence of elevations in creatine kinase.
• Participant has diabetes mellitus (types 1 or 2).
• Participant has mental conditions such as schizophrenia, bipolar disorder or major depressive disorder that has not been under control within 1 year prior to screening.
• Participant has severe behavioral or cognitive problems that preclude participation in the study.
• Participant has a history of suicide attempt, suicidal behavior or has any suicidal ideation within 1 year prior to screening that meets criteria at a level of 4 or 5 by using the Columbia-Suicide Severity Rating Scale (C-SSRS) or who is at significant risk to commit suicide.
• Participant has undergone an inpatient hospitalization within the 30 days prior to the randomization or has a planned hospitalization or a surgical procedure during the study, which may affect the study assessments.
• Participant has clinically significant respiratory disease (such as chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, lung infections including tuberculosis, sarcoidosis, thoracic endometriosis, pulmonary fibrosis and lung cancers) and/or cardiac disease (medical history or current clinical findings) or prior interventional cardiac procedure (e.g., left heart catheterization which resulted in angioplasty/percutaneous coronary intervention, balloon valvuloplasty, etc.) within 3 months prior to randomization.
• Participant has a pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy device, or has a mean corrected QT interval using Fridericia's formula (QTcF) \> 450 msec for male participants and \> 470 msec for female participants at screening or randomization. If QTcF exceeds these limits, 1 additional triplicate ECG can be taken on the same day in order to determine the participant's eligibility.
• Participant has ECG evidence of acute ischemia, atrial fibrillation or active conduction system abnormalities at screening, with the exception of any of the following:

Sponsors & Collaborators

• Astellas Pharma Global Development, Inc.: lead

Study Sites (1)

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Location

Related Links

• Link to plain language summary of the study on the Trial Results Summaries website

Study Officials

• Senior Medical Director

  Astellas Pharma Global Development, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 20, 2021
• First Posted: April 22, 2021
• Study Start: June 14, 2021
• Primary Completion: December 16, 2022
• Study Completion: December 16, 2022
• Last Updated: April 16, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)